Navigation Links
Lymphoblastic in Medical News

Micromet, Inc. Reports Second Quarter 2009 Financial Results

... of blinatumomab phase 2 data in acute lymphoblastic leukemia (ALL) at the 14(th) Congress of the ... forward to initiating a pivotal trial in acute lymphoblastic leukemia in 2010," stated Christian Itin, Ph.D., ... trial for the treatment of patients with acute lymphoblastic leukemia (ALL), and in a phase 1 clinical trial ...

2009 recipient of minority scholar award begins clinical research on leukemia

... research into the pathogenesis of T-cell acute lymphoblastic leukemia (T-ALL) this month. The award, the ... the Molecular Pathogenesis of T-Cell Acute lymphoblastic Leukemia Using Zebrafish Genetics and Small ... the molecular pathogenesis of T-cell acute lymphoblastic leukemia. Specifically, Dr. Gutierrez is ...

For Kids With Leukemia, Radiation May Be Safe to Skip

... for most children with newly diagnosed acute lymphoblastic leukemia, new research has found. In fact, ... cure up to 90 percent of all children with acute lymphoblastic leukemia without the use of cranial irradiation," ... Memphis, Tenn. "Survivors of childhood acute lymphoblastic leukemia can now enjoy excellent quality of life, ...

New genes involved in acute lymphoblastic leukemia play fundamental role in prognosis of the disease

... a fundamental role in the prognosis of acute lymphoblastic leukemia as well as in response to treatment, ... - 179 children and 174 adults - with acute lymphoblastic leukaemia). The results open up new therapeutic ... of results. It is notable that acute lymphoblastic leukaemia is the most common oncological illness ...

In Kids, Genes May Affect Leukemia Treatment

... affect the way children respond to treatment for lymphoblastic leukemia, researchers report. Although about ... studied genetic variations in 487 children with lymphoblastic leukemia. Their goal was to find evidence of ... that almost 20 percent of children treated for lymphoblastic leukemia suffer cognitive damage from ...

Gene Governs Response to Leukemia Chemotherapy

... Acute lymphoblastic leukemia is most common pediatric cancer ... leukemia cells predicts which children with acute lymphoblastic leukemia are more likely to relapse. The ... subsets of patients. "The treatment of acute lymphoblastic leukemia (ALL) is really one of the success ...

Novel treatments show improvements in survival and response rates for leukemia and lymphoma

... early in the treatment of children with acute lymphoblastic leukemia, the most common type of childhood ... One-Third of All Relapses in Childhood Acute lymphoblastic Leukemia: Results of an International Randomized ... of event-free survival in children with acute lymphoblastic leukemia. Dexamethasone was associated with a ...

Novel Treatments Demonstrate Improvements in Overall Survival and Response Rates in Difficult-To-Treat Forms of Leukemia and Lymphoma

... early in the treatment of children with acute lymphoblastic leukemia, the most common type of childhood ... One-Third of All Relapses in Childhood Acute lymphoblastic Leukemia: Results of an International Randomized ... of event-free survival in children with acute lymphoblastic leukemia. Dexamethasone was associated with a ...

St. Jude Discovery Offers New Avenues to Understanding an Aggressive Form of Leukemia

... mutations can cause an aggressive form of acute lymphoblastic leukemia could lead to new ... of an aggressive and often-fatal form of acute lymphoblastic leukemia (ALL). These defects, known as ... system. "The vast majority of pediatric acute lymphoblastic leukemias are of B-cell lineage," Downing ...

Stem cells give clues to understanding cancer and make breakthrough in childhood leukaemia

... the most common form of childhood cancer, acute lymphoblastic leukaemia (ALL). The research should lead to less ... presented findings of his research on acute lymphoblastic leukaemia (ALL), which has now been published in ... we can now test whether the treatment of acute lymphoblastic leukaemia in children can be correlated with ...

St. Jude finds more than 100 gene variations linked with response to leukemia treatment

... the Children's Oncology Group (COG) have discovered in children with acute lymphoblastic leukemia (ALL) scores of inherited genetic variations that clinicians ... are representative of the array of antileukemic medications used to treat lymphoblastic leukemia. Pharmacokinetics comprises the various biochemical fates of a ...

Micromet, Inc. Reports Second Quarter 2008 Financial Results

... ongoing phase 2 clinical trial of blinatumomab in patients with acute lymphoblastic leukemia (ALL). -- Finally, Micromet expects that its collaboration ... is in a phase 2 clinical trial for the treatment of patients with acute lymphoblastic leukemia and in a phase 1 clinical trial for the treatment of patients ...

St. Jude discovery offers new avenues to understanding an aggressive form of leukemia

... to initiate most cases of an aggressive and often-fatal form of acute lymphoblastic leukemia (ALL). These defects, known as "cooperating oncogenic ... are part of the immune system. "The vast majority of pediatric acute lymphoblastic leukemias are of B-cell lineage," Downing said. Among the ALL patients, ...

Leicester scientist announces 'unexpected and exciting advance' in study of cancer type

... the research project at the University of Leicester investigating acute lymphoblastic leukaemia (ALL). Professor Martin Dyer, in the Universitys Department ... novel chromosomal translocations in children and young adults with acute lymphoblastic leukaemia. These translocations arise following breaks within DNA that ...

Micromet Receives Regulatory Approval to Conduct a Phase 2 Clinical Trial Investigating MT103 (MEDI-538) in Patients with Acute Lymphoblastic Leukemia

... conduct of a phase 2 clinical trial testing MT103 in patients with acute lymphoblastic leukemia (ALL) in Germany. MT103, a BiTE(R) antibody targeting the CD19 ... granted MedImmune exclusive rights for MT103 for North America. Acute lymphoblastic leukemia is a highly aggressive form of B-cell leukemia. Currently, ...

DEET in Bug Spray Tied to Neural Damage in Mice

... exposure to acetylcholinesterase inhibitors and the Gulf War illness suffered by many veterans. Organophosphates have also been linked with acute lymphoblastic leukemia, the most common form of leukemia in children. More information The U.S. Environmental Protection Agency has more on DEET. ...

Common household pesticides linked to childhood cancer cases in Washington area

... at the Georgetown's Lombardi Comprehensive Cancer Center finds a higher level of common household pesticides in the urine of children with acute lymphoblastic leukemia (ALL), a cancer that develops most commonly between three and seven years of age. The findings are published in the August issue of the ...

Comprehensive Look at Rare Leukemia Finds Relatively Few Genetic Changes Launch Disease

... mutations involve a single chemical change in the molecular building blocks of DNA. The data demonstrated that, in contrast to pediatric acute lymphoblastic leukemia (ALL), AML is characterized by a very low burden of mutations. The researchers found slightly more than two CNAs per AML patient, and less ...

New strategy in tumor treatment

... to 70 percent of lung, pancreatic and biliary tract cancer, melanoma, glioblastoma, osteosarcoma, soft-tissue sarcoma, mesothelioma, and T-cell acute lymphoblastic leukemia. Although information on the incidence of MTAP-deficiency in breast cancer is still limited, researchers believe it is probably ...

Breast cancer drug shows promise against serious infections

... third most common cause of blood stream infection in premature infants in the neonatal intensive care unit. The survival rate for children with acute lymphoblastic leukemia is about 95 percent, but if they acquire a Candida albicans fungal infection, that drops to 80 percent. Bacterial meningitis has a 5 percent ...

Phase 1 Study Initiated with Micromet Anti-GM-CS Human Antibody MT203

... are currently in clinical trials. Its BiTE antibody blinatumomab (MT103) is in a phase 2 clinical trial for the treatment of patients with acute lymphoblastic leukemia (ALL), and in a phase 1 clinical trial for the treatment of patients with non-Hodgkin's lymphoma (NHL). A second BiTE antibody, MT110, is in ...

Taking Aim at Relapse of Leukemia in Kids

... blood-borne childhood cancer, a finding that may lead to the development of drugs that block these molecules and prevent relapse. In T-cell acute lymphoblastic leukemia (T-ALL), which primarily strikes children and adolescents, the bone marrow makes too many white blood cells. "In general, [T-ALL] is ...

Genes May Raise Risk of Neuroblastoma in Kids

... discovered a protein receptor on the outer surface of cells that's involved in the spread of leukemia. Specifically, they looked at T-cell acute lymphoblastic leukemia, which strikes mostly children. Though treatable, the relapse rate for this cancer is high and, once it recurs, it is seldom treatable, ...

USC researchers identify DNA mutation that occurs at beginning point of T-cell lymphoma

... occurs when two chromosomes break and the resulting fragments are reassembled in an exchange. Researchers specifically looked at T cell acute lymphoblastic lymphomas (ALL). ALL accounts for half of all childhood cancers under the age of five, and T cell ALL represents about 10 percent of ALL. The USC ...

Micromet, Inc. Reports First Quarter 2009 Financial Results

... in clinical trials. Its BiTE antibody blinatumomab (MT103) is being evaluated in a phase 2 clinical trial for the treatment of patients with acute lymphoblastic leukemia (ALL), and in a phase 1 clinical trial for the treatment of patients with non-Hodgkin's lymphoma (NHL). A second BiTE antibody, MT110, is ...

American Cancer Society awards 143 research grants to investigators at 83 institutions nationwide

... a doctoral student at the University of Hawai'i, will explore ways to improve adherence to oral maintenance chemotherapy in young patients with acute lymphoblastic leukemia. Although overall survival with contemporary therapy now exceeds 80 percent, 5-year survival rates in some populations vary significantly, ...

Researchers find drug that inhibits acute leukemia cell growth

... the drug in the future, explained Ghisoli. Acute leukemia is the most common cancer in children, according to the American Cancer Society. Acute lymphoblastic leukemia, the more common type, has a cure rate of 80 percent, but children with the rarer type, AML, have only a 50 percent chance of a cure in ...

Gene Studies Reveal Cancer's Secrets

... researchers led by Dr. Charles Mullighan, an assistant member at St. Jude Children's Research Hospital, Memphis, found that children with acute lymphoblastic leukemia (ALL) who have mutations in the JAK tyrosine kinase gene generally have poor outcomes, including a higher risk of recurrence of their ....

Survey: Few physicians support private banking of umbilical cord blood

... Few of the respondents said they would choose a patient's own cord blood over other alternatives as a source of stem cells for treatment of acute lymphoblastic leukemia. By contrast, more than half said they would use an individual's own cord blood to treat high-risk neuroblastoma, or to treat severe ...

SuperGen Reports 2008 Fourth Quarter and Year-End Financial Results

... presentation announced that the Company's oral PIM kinase inhibitor, SGI-1776, is active both in vitro and in vivo in preclinical models of acute lymphoblastic leukemia (ALL) (Abstract #1922). In a poster presentation entitled "Inhibiting PIM-1 is effective in vitro and in vivo against ALL: A novel ...

Blood Drive Held in Honor of Sewell, NJ Resident - Ellie Koerner

... (1-800-448-3543). (Logo: http://www.newscom.com/cgi-bin/prnh/20081216/DC52619LOGO ) Koerner is battling a type of cancer called Acute lymphoblastic Leukemia (ALL). It occurs in one out of every 29,000 children in the United States each year. The blood drive is located at Grenloch Community ...

Micromet To Present at the ROTH 21st Annual Orange County Growth Stock Conference

... Company's lead program is a BiTE antibody known as blinatumomab, or MT103. It is in a phase 2 clinical trial for the treatment of patients with acute lymphoblastic leukemia and a phase 1 clinical trial for the treatment of patients with non-Hodgkin's lymphoma. Micromet is developing blinatumomab in collaboration ...

New Data Published in Immunobiology Describe Mode of Action of BiTE Antibody MT110

... Company's lead program is a BiTE antibody known as blinatumomab, or MT103. It is in a phase 2 clinical trial for the treatment of patients with acute lymphoblastic leukemia and a phase 1 clinical trial for the treatment of patients with non-Hodgkin's lymphoma. Micromet is developing blinatumomab in collaboration ...

Dana-Farber Researcher Named Millennium Pharmaceuticals Career Development Scholar of The Leukemia & Lymphoma Society

... to identify the molecules that allow cancer cells to proliferate by inhibiting apoptosis in patients with chronic lymphocytic leukemia, acute lymphoblastic leukemia and diffuse large B-cell lymphoma. His lab has been testing novel targeted therapies that attack these molecules and selectively kill ...

Childhood Leukemia Subtype Resists Treatment

... say they have identified a rare subtype of a childhood leukemia that does not respond well to treatment. Those with the subtype of acute lymphoblastic leukemia (ALL) have a BCR-ABL1 fusion gene. In the Dutch and German genetic analysis of children recently diagnosed with ALL, those with this gene ...

Gene abnormality found to predict childhood leukemia relapse

... Scientists have identified mutations in a gene that predict a high likelihood of relapse in children with acute lymphoblastic leukemia (ALL). Although the researchers caution that further research is needed to determine how changes in the gene, called IKZF1 or IKAROS, lead ...

Adult survivors of childhood leukemia have lower bone mineral density, study finds

... The average age of the survivors was 30, and they had been treated an average of 24 years ago for the most common type of childhood cancer, acute lymphoblastic leukemia. According to the World Health Organization, 11 percent of 30-year-old men and 19 percent of 30-year-old women on average have low bone ...

Micromet, Inc. to Host Webcast and Conference Call to Discuss Blinatumomab Data Presented at American Society of Hematology Annual Meeting

... Company's lead program is a BiTE antibody known as blinatumomab, or MT103. It is in a phase 2 clinical trial for the treatment of patients with acute lymphoblastic leukemia and a phase 1 clinical trial for the treatment of patients with non-Hodgkin's lymphoma. Micromet is developing blinatumomab in collaboration ...

Micromet to Present at the Piper Jaffray 20th Annual Health Care Conference

... lead program is a BiTE(R) antibody known as blinatumomab, or MT103. It is in a phase 2 clinical trial for the treatment of patients with acute lymphoblastic leukemia and a phase 1 clinical trial for the treatment of patients with non-Hodgkin's lymphoma. Micromet is developing blinatumomab in collaboration ...

Marlo Thomas and St. Jude Children's Research Hospital(R) Kick Off The 5th Anniversary of the Thanks and Giving(R) Campaign Asking America to Support St. Jude While Shopping this Holiday Season

... for childhood cancer from less than 20 percent to more than 70 percent overall. When St. Jude opened its doors in 1962, the survival rate for acute lymphoblastic leukemia (ALL), the most common form of childhood cancer, was 4 percent. Today, the survival rate for this once deadly disease is 94 percent thanks ...
Other Contents
(Date:8/28/2014)... Protected areas conserve biodiversity and more action is needed ... areas, researchers say. , Published in PLOS ONE ... University of Exeter, used meta-analysis - combining results from ... years of research into these areas, to determine whether ... School of Biological Sciences, said protecting an area from ...
(Date:8/28/2014)... Many of the world,s most important crop-producing countries will ... the century if current trends continue, according to a ... More than one-in-ten pest types can already be found ... crops. If this spread advances at its current rate, ... countries will be overwhelmed by pests within the next ...
(Date:8/27/2014)... , Aug. 27, 2014  WaferGen Bio-systems, Inc. (NASDAQ: ... announced underwritten public offering of units of common stock ... for gross proceeds of $20 million, prior to deducting ... the Company.  The shares and warrants are immediately separable ... unit sold in the offering consists of 2,000 shares ...
Breaking Biology News(10 mins):Protected areas proven to protect biodiversity 2New study charts the global invasion of crop pests 2WaferGen Bio-Systems Announces Successful Completion of Public Offering Raising $20 Million 2WaferGen Bio-Systems Announces Successful Completion of Public Offering Raising $20 Million 3
(Date:8/29/2014)... August 29, 2014 Senior Independence ... operations & business development. , Rees has been with ... of business development. , A wholly owned subsidiary of ... provides older adults with options, including personalized home health ... (e.g., meal preparation) and therapeutic adult day centers. , ...
(Date:8/29/2014)... (PRWEB) August 29, 2014 Last week, ... the sixth consecutive monthly gain. Industrial production rose to 0.4% ... in industrial production is the single largest boost since February ... a percentage point since February as well – an increase ... Capacity utilization rose to a 79.2% rate, which is a ...
(Date:8/29/2014)... who have been hospitalized for a burn as a child ... according to new research at the University of Adelaide ... has been conducted by the University,s Centre for Traumatic Stress ... suffered some form of mental illness and 30% suffered depression ... published in the journal Burns , also ...
(Date:8/29/2014)... New ESC registries are being launched on cardiac ... comes as the long-term phase of the cardiomyopathy ... failure patients conducted in collaboration with the Organisation ... outcomes evaluation. , The registries are all part ... Professor Roberto Ferrari, Chairperson of EORP, said: "The ...
(Date:8/29/2014)... (PRWEB) August 29, 2014 Glendale Botox ... special promotion on Botox throughout the month of September. This ... purchase of two syringes of Juvederm. Patients can take advantage ... their skin. The Glendale Botox experts will work with patients ... needs. , What is Botox? , Botox is ...
Breaking Medicine News(10 mins):Health News:Senior Independence Promotes Rees to Vice President of Operations & Business Development 2Health News:LeaseQ Announces That Recent Industrial Production Report Spells Good Things For The Equipment Leasing Industry 2Health News:LeaseQ Announces That Recent Industrial Production Report Spells Good Things For The Equipment Leasing Industry 3Health News:Intervention needed for survivors of childhood burns 2Health News:New ESC registries launched on cardiac oncology and ACS 2Health News:New ESC registries launched on cardiac oncology and ACS 3Health News:New ESC registries launched on cardiac oncology and ACS 4Health News:Glenoaks Laser Center is Now Offering a Special Promotion on Botox for the Month of September 2
Other TagsOther Tags